HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Innovative Gastroscope Enhances Imaging Capabilities

By HospiMedica International staff writers
Posted on 21 Nov 2013
Image: The tip of the Fuse 1G Gastroscope (Photo courtesy of EndoChoice).
Image: The tip of the Fuse 1G Gastroscope (Photo courtesy of EndoChoice).
A flexible endoscope with an extended 245-degree field of view facilitates diagnoses in the upper gastrointestinal (GI) tract.

The Fuse 1G Gastroscope employs Full Spectrum Endoscopy technology using two cameras, while traditional systems have just one camera. This allows observation of nearly twice as much surface area, allowing clinicians to identify adenomas or precancerous lesions in and behind the folds that occur naturally in the colon and stomach anatomy, problem areas that can easily go undetected when using traditional endoscopes. Optimal imaging is enabled using built-in light emitting diode (LED) lighting around the tip to provide illumination.

Images are displayed on three high-definition (HD) screens, allowing visualization of more of the GI tract. The system uses a FuseBox control unit with the FusePanel image management system to interface with electronic medical record (EMR) systems for tracking of patients, physician IDs, and the procedures performed. It also enables saving of every image for viewing or printing later. Images can be captured remotely or can be exported in PDF format to be used on other EMR systems. The Fuse 1G Gastroscope is a product of EndoChoice (Atlanta, GA, USA), and has been approved by the US Food and Drug Administration (FDA).

“We are 100% focused on serving the GI professionals so they can give the best possible care to their patients,” said Mark Gilreath, founder and CEO of EndoChoice. “This clearance by the FDA is yet another milestone in our efforts to make the Fuse system available to more hospitals and clinics.”

“We have a national colorectal cancer screening program in the United States wherein most people should get screened for colorectal cancer, but not all patients follow these guidelines,” said Prof. Douglas K. Rex, MD, of Indiana University (Indianapolis, USA). “The data from the Full Spectrum Endoscopy Tandem study would indicate that Fuse is a radical improvement over the tools we've used in the past to fight GI disease.”

Related Links:

EndoChoice

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Neonatal Ventilator Simulation Device
Disposable Infant Test Lung
Half Apron
Demi

Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more